Back to Journals » Open Access Journal of Clinical Trials » Volume 10

Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)

Authors Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H

Received 31 October 2017

Accepted for publication 15 December 2017

Published 16 February 2018 Volume 2018:10 Pages 13—18

DOI https://doi.org/10.2147/OAJCT.S155706

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Professor Arthur Frankel


Tatsunori Shimoi,1 Akihiko Shimomura,1 Tadahiko Shien,2 Yukari Uemura,3 Hiroaki Kato,4 Masahiro Kitada,5 Tatsuya Toyama,6 Tomohiko Aihara,7 Hirofumi Mukai8

1Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan; 3Division of Biostatistics, Clinical Research Support Center, Tokyo University Hospital, Tokyo, Japan; 4Department of Thoracic Surgery, Teine Keijinkai Hospital, Sapporo, Japan; 5Department of Surgery, Asahikawa Medical University, Asahikawa, Japan; 6Department of Oncology, Immunology and Surgery, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan; 7Department of Breast Surgery, Keimeikai-Aihara Hospital, Osaka, Japan; 8Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

Background:
This is a randomized, multicenter, open-label, Phase II study designed to evaluate the efficacy of everolimus added to continuous aromatase inhibitor (AI) administration in patients who had maintained stable disease or a better response for at least 5 months.
Patients and methods: Patients will be randomized to everolimus and standard therapy groups (1:1 ratio). In the everolimus group, patients will receive everolimus in addition to the AI agent. The standard therapy group will continue AI alone treatment. The primary endpoint is progression-free survival. Target accrual is 130 patients with a two-sided type I error rate of 10% and 80% power to detect 35% risk reduction.
Conclusion: The Chloe trial will provide important information about the efficacy and safety of adding everolimus to AI in patients with estrogen receptor-positive and human epidermal growth factor 2-negative metastatic breast cancer.

Keywords: hormone receptor-positive, breast cancer, aromatase inhibitor, everolimus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]